Millennium Magazine_3rdEd

165 Millennium - A Marquis Who’s Who Magazine SCIENCES, PHARMACEUTICALS AND BIOTECHNOLOGY D r. David R. Elmaleh is a world-renowned scientist, educator and entrepreneur whose expertise is in biopharmaceuticals. The recipient of a BSc in physics and chemistry, an MSc in physical organic chemistry and a PhD in organic chemistry from the Hebrew University of Jerusalem, he has been the founder of such pharmaceutical companies as Imaging Biopharmaceuticals, known as Molecular Insight Pharmaceuticals, Mersana Therapeutics, FluoroPharma, PureTech and AZTherapies, where he currently serves as Chairman and Chief Executive Officer. AZTherapies was founded in 2011 to lead drug development for the clinical unmet needs of treatment of neurodegeneration associated with aging, such as Alzheimer’s disease (AD), stroke and ALS. Dr. Elmaleh advanced AZTherapies to a late stage Phase III clinical trial in early AD subjects. He was named one of the biotechnology industry’s top 13 serial entrepreneurs by Genetic Engineering & Biotechnology News. Dr. Elmaleh is the inventor of several drugs that are used in the clinic or late- stage clinical trials, including the radiopharmaceutical 2FDG, which has been approved as a PET imaging agent for the diagnosis of cancer, Beta-methyl modified fatty acid as indicators of heart metabolic integrity and Altropane for more accurate diagnosing of disease. His research brought about drug design principals for developing drugs that mimic the normal biochemical pathway to be altered for drug trapping in metabolic state, allowing a static image collection of internal organs. Named on intellectual property platforms for treating and monitoring responses to therapy in atherosclerosis, neuroinflammation, CNS and cancer, he is a co-author of over 130 publications and holds more than 110 issued and pending patents. Dr. Elmaleh is an associate professor at Harvard University and Director of Contrast Media Chemistry at Massachusetts General Hospital. His role in the development of Altropane led to its nomination as one of the 25 most valuable brain-related inventions of the decade. As someone who believes that the next scientific frontier is in the fields of neurobiology and neurodegeneration, he has greatly enjoyed designing and developing drugs for the diagnosis and treatment of Parkinson’s and Alzheimer’s diseases. DAVID R. ELMALEH, PHD CHIEF EXECUTIVE OFFICER, CHAIRMAN AZTherapies Boston, MA